Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) Operating Expenses (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Operating Expenses for 4 consecutive years, with $40.1 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 163.06% to $40.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.2 million through Dec 2025, up 88.07% year-over-year, with the annual reading at $110.2 million for FY2025, 88.07% up from the prior year.
  • Operating Expenses for Q4 2025 was $40.1 million at LENZ Therapeutics, up from $31.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $40.1 million in Q4 2025, with the low at $12.6 million in Q1 2023.
  • Average Operating Expenses over 4 years is $21.5 million, with a median of $19.9 million recorded in 2023.
  • The sharpest move saw Operating Expenses crashed 51.4% in 2023, then skyrocketed 163.06% in 2025.
  • Over 4 years, Operating Expenses stood at $26.8 million in 2022, then dropped by 25.74% to $19.9 million in 2023, then decreased by 23.36% to $15.2 million in 2024, then surged by 163.06% to $40.1 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $40.1 million, $31.4 million, and $21.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.